0001213900-21-012025.txt : 20210226 0001213900-21-012025.hdr.sgml : 20210226 20210226141623 ACCESSION NUMBER: 0001213900-21-012025 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20210222 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210226 DATE AS OF CHANGE: 20210226 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Augmedix, Inc. CENTRAL INDEX KEY: 0001769804 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389] IRS NUMBER: 833299164 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-56036 FILM NUMBER: 21687292 BUSINESS ADDRESS: STREET 1: 1161 MISSION STREET STREET 2: SUITE LL CITY: SAN FRANCISC STATE: CA ZIP: 94103 BUSINESS PHONE: 561-989-2208 MAIL ADDRESS: STREET 1: 1161 MISSION STREET STREET 2: SUITE LL CITY: SAN FRANCISC STATE: CA ZIP: 94103 FORMER COMPANY: FORMER CONFORMED NAME: Malo Holdings Corp DATE OF NAME CHANGE: 20190305 8-K 1 ea136641-8k_augmedix.htm CURRENT REPORT
0001769804 false 0001769804 2021-02-22 2021-02-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): February 22, 2021

 

 

 

AUGMEDIX, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   000-56036   83-3299164

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

1161 Mission Street

Suite B-100

San Francisco, California

   94103
(Address of principal executive offices)   (Zip Code)

 

(888) 669-4885

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

 

    

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act: none.

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 1.01. Entry into a Material Agreement.

 

On February 22, 2021, Augmedix, Inc., a Delaware corporation (the “Company”), entered into a Lock-Up Agreement, by and between the Company and certain stockholders of the Company (such stockholders, the “Holders”, and the agreement, the “Lock-Up Agreement”).

 

The Lock-Up Agreement provides for, among other things, a limitation on the ability of the Holders to make dispositions of 80% of each Holder’s securities of the Company for a period commencing with the Company’s listing of its shares of Common Stock on an over-the-counter market as reported by the OTC Markets Group Inc. and ending 180 days thereafter, subject to certain early release conditions.

 

The Lock-Up Agreement is furnished as Exhibit 10.1 to this current report on Form 8-K and is incorporated herein by reference. The foregoing description of the Lock-Up Agreement does not purport to be complete and is qualified in its entirety by reference to the Lock-Up Agreement.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

10.1Lock-Up Agreement, dated February 22, 2021, by and between Augmedix, Inc. and the parties thereto.
   
104Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.

 

1

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  AUGMEDIX, INC.
     
Date: February 26, 2021 By: /s/ Emmanuel Krakaris
    Emmanuel Krakaris
    President, Chief Executive Officer, Secretary and Director

 

 

2

 

 

 EX-10.1 2 ea136641ex10-1_augmedix.htm LOCK-UP AGREEMENT, DATED FEBRUARY 22, 2021, BY AND BETWEEN AUGMEDIX, INC.

Exhibit 10.1

 

FORM OF LOCK-UP AGREEMENT

 

February 22, 2021

DCM VI, L.P. and Affiliates

Mark Tompkins

Redmile Group, LLC and Affiliates

McKesson Ventures LLC

 

Ladies and Gentlemen:

 

In connection with Augmedix, Inc., a Delaware corporation (the “Company”) listing its publicly available shares of Common Stock (the “Shares”), par value $0.0001 per share, pursuant to the Registration Statement on Form S-1, as amended, that has been filed with the Securities and Exchange Commission (the “SEC”) on an over-the-counter market as reported by OTC Markets Group Inc. (such exchange, the “OTC”), the undersigned signatory (the “Stockholder”) hereby agrees to this lock-up agreement (the “Agreement”), and that, for good and valuable consideration which is hereby acknowledged, the Stockholder will not, with respect to the shares set forth on Exhibit A hereto, during the period commencing upon the listing of the shares on the OTC (the “Listing Date”) and ending on the date that is 180 days after the Listing Date (the “Restricted Period”):

 

(i)offer, pledge, sell, contract to sell, sell any option, warrant or contract to purchase, purchase any option, warrant or contract to sell, grant any option, right or warrant to purchase, make any short sale or otherwise transfer or dispose of or lend, directly or indirectly, any Shares or any securities convertible into or exercisable or exchangeable for, or that represent a right to receive, Shares (including without limitation, Shares or such other securities of the Company which may be deemed to be beneficially owned by the Stockholder in accordance with the rules and regulations of the SEC and securities of the Company which may be issued upon exercise of a stock option or warrant), in each case, that are currently owned of record or beneficially (including holding as a custodian) by the Stockholder as set forth on Exhibit A (collectively, the “Stockholder’s Shares”), or publicly disclose the intention to make any such offer, sale, pledge, grant, transfer or disposition;

 

(ii)enter into any swap, short sale, hedge or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Stockholder’s Shares;

 

(iii)make any demand for or exercise any right with respect to the registration of any of the Stockholder’s Shares or any security convertible into or exercisable or exchangeable for Shares; or

 

(iv)publicly disclose the intention to do any of the foregoing.

 

 

 

 

The restrictions and obligations contemplated by this Agreement shall not apply to:

 

(a)transfers of the Stockholder’s Shares:

 

(i)if the Stockholder is a natural person, (A) to any person related to the Stockholder by blood or adoption who is a member of the immediate family of the Stockholder, or by marriage or domestic partnership (a “Family Member”), or to a trust formed for the benefit of the Stockholder or any of the Stockholder’s Family Members, (B) to the Stockholder’s estate, following the death of the Stockholder, by will, intestacy or other operation of law, (C) as a bona fide gift to a charitable organization, (D) by operation of law pursuant to a qualified domestic order or in connection with a divorce settlement or (E) to any partnership, corporation or limited liability company which is controlled by the Stockholder and/or by any such Family Member(s);

 

(ii)if the Stockholder is a corporation, partnership, limited liability company or other business entity, (A) to another corporation, partnership, limited liability company or other business entity that is a direct or indirect affiliate (as defined under Rule 12b-2 of the Exchange Act) of the Stockholder, including investment funds or other entities that control, are controlled by or are under common control or management with the Stockholder, (B) as a distribution or dividend to equity holders (including, without limitation, general or limited partners, members and stockholders) of the Stockholder (including upon the liquidation and dissolution of the Stockholder pursuant to a plan of liquidation approved by the Stockholder’s equity holders), (C) as a bona fide gift to a charitable organization or not-for-profit institution, (D) transfers or dispositions not involving a change in beneficial ownership, (E) in connection with the sale or other bona fide transfer in a single transaction of all or substantially all of the Stockholder’s capital stock, partnership interests, membership interests or other similar equity interests, as the case may be, or all or substantially all of the Stockholder’s assets, in any such case not undertaken for the purpose of avoiding the restrictions imposed by this Agreement, (F) pursuant to an order of a court or regulatory agency or (G) with the prior written consent of Company; or

 

(iii)if the Stockholder is a trust, to any grantors or beneficiaries of the trust;

 

provided that, in the case of any transfer or distribution pursuant to clauses (a)(i) and (a)(ii)(C), such transfer is not for value and in the case of any transfer or distribution pursuant to this clause (a) each donee, heir, beneficiary or other transferee or distributee shall agree in writing to be bound by the terms and conditions of this Agreement with respect to the Shares or such other securities that have been so transferred or distributed and either the Stockholder or such transferee provides Company with a copy of such agreement promptly upon consummation of any such transfer;

 

(b) (i) the exercise of an option (including a net exercise of an option) to purchase shares of the Company’s Common Stock, (ii) any related transfer of shares of the Company’s Common Stock to the Company for the purpose of paying the exercise price of such options or for paying taxes (including estimated taxes) due as a result of the exercise of such options (or the disposition to the Company of any shares of restricted stock granted pursuant to the terms of any employee benefit plan or restricted stock purchase agreement) and (iii) any transfer or sale of shares of the Company’s Common Stock to the Company or into the market for the purpose of paying taxes (including estimated taxes) due in connection with the vesting of, or issuance of shares under, restricted stock unit awards granted pursuant to the terms of any equity incentive plan; provided that, in the case of any exercise of an option or any transfer or sale of shares to the Company under clauses (i) and (iii), the underlying shares of the Company’s Common Stock shall continue to be subject to the restrictions on transfer set forth in this Agreement;

 

2

 

 

 

(c)  the establishment of a trading plan pursuant to Rule 10b5-1 under the Exchange Act for the transfer of the Company’s Common Stock; provided that such plan does not provide for any transfers of the Company’s Common Stock during the Restricted Period;

 

(d)  transfers or dispositions of by the Stockholder’s Shares purchased by the Stockholder on the open market; or

 

(e)  transfers or distributions pursuant to a bona fide third party tender offer, merger, consolidation or other similar transaction made to all holders of Shares involving a change of control of Company (including entering into any lock-up, voting or similar agreement pursuant to which the undersigned may agree to transfer, sell, tender or otherwise dispose of shares of Shares (or any security convertible into or exercisable for Shares), or vote any shares of Shares in favor of any such transaction or taking any other action in connection with any such transaction), provided that the restrictions set forth in this Lock-Up Agreement shall continue to apply to the Stockholder’s Shares should such tender offer, merger, consolidation or other transaction not be completed;

 

and provided, further, that, with respect to each of (a) and (b) above, no filing by any party (including any donor, donee, transferor, transferee, distributor or distributee) under the Exchange Act (other than (i) a filing at any time on a Form 5 or (ii) a required filing on a Schedule 13D or Schedule 13G (or Schedule 13D/A or Schedule 13G/A)), or other public announcement shall be required or shall be made voluntarily in connection with such transfer or disposition during the Restricted Period (other than in respect of a required filing under Section 16(a) of the Exchange Act in connection with the exercise of an option to purchase Shares following such individual’s termination of service relationship (including service as a director) with Company that would otherwise expire during the Restricted Period, provided that reasonable notice shall be provided to Company prior to any such filing, or in respect of a required filing under Section 16(a) of the Exchange Act in connection with the settlement of any equity award granted pursuant to the terms of any equity incentive plan). For purposes of this Agreement, “immediate family” shall mean any relationship by blood, marriage or adoption, not more remote than first cousin.

 

Any attempted transfer in violation of this Agreement will be of no effect and null and void, regardless of whether the purported transferee has any actual or constructive knowledge of the transfer restrictions set forth in this Agreement, and will not be recorded on the share register of Company. In furtherance of the foregoing, the Stockholder agrees that Company and any duly appointed transfer agent for the registration or transfer of the securities described herein are hereby authorized to decline to make any transfer of securities if such transfer would constitute a violation or breach of this Agreement. Company may cause the legend set forth below, or a legend substantially equivalent thereto, to be placed upon any certificate(s) or other documents, ledgers or instruments evidencing the Stockholder’s ownership of Shares:

 

THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO AND MAY ONLY BE TRANSFERRED IN COMPLIANCE WITH A LOCK-UP AGREEMENT, A COPY OF WHICH IS ON FILE AT THE PRINCIPAL OFFICE OF THE COMPANY.

 

3

 

 

The Stockholder hereby represents and warrants that the Stockholder has full power and authority to enter into this Agreement. All authority herein conferred or agreed to be conferred and any obligations of the Stockholder shall be binding upon the successors, assigns, heirs or personal representatives of the Stockholder.

 

This Agreement shall terminate automatically and the Stockholder shall automatically be released from all restrictions and obligations under this Agreement upon the earlier of (i) the expiration of the Restricted Period, or (ii) immediately prior to the Company’s listing of the Shares on the Nasdaq Stock Market, the New York Stock Exchange or the NYSE American. The Stockholder understands the Company is proceeding with the registration of the Shares on the OTC in reliance upon this Agreement.

 

Any and all remedies herein expressly conferred upon the Company will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by law or equity, and the exercise by the Company of any one remedy will not preclude the exercise of any other remedy. The Stockholder agrees that irreparable damage would occur to the Company in the event that any provision of this Agreement were not performed in accordance with its specific terms or were otherwise breached. It is accordingly agreed that the Company shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof in any court of the United States or any state having jurisdiction, this being in addition to any other remedy to which the Company is entitled at law or in equity, and the Stockholder waives any bond, surety or other security that might be required of the Company with respect thereto.

 

This Agreement and any claim, controversy or dispute arising under or related to this Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, without regard to the conflict of laws principles thereof.

 

This Agreement, and any certificates, documents, instruments and writings that are delivered pursuant hereto, constitutes the entire agreement and understanding of the Company and the Stockholder in respect of the subject matter hereof and supersedes all prior understandings, agreements or representations by or among the Company, and the Stockholder, written or oral, to the extent they relate in any way to the subject matter hereof. The delivery of a fully executed Agreement by the Stockholder by facsimile or electronic transmission in .pdf format shall be sufficient to bind the Stockholder to the terms and conditions of this Agreement. Irrespective of negotiations among the parties or the exchanging of drafts of this Agreement, this Agreement shall not constitute or be deemed to evidence a contract, agreement, arrangement or understanding between the parties hereto unless and until this Agreement is executed by all parties hereto.

 

(Signature Pages Follow)

 

4

 

 

  Very truly yours,
   
  Augmedix, Inc.
   
  Manny Krakaris
  (Print Name of Stockholder)
   
  /s/ Manny Krakaris
  (Signature)
   
  Manny Krakaris CEO
(Name and Title of Signatory, if Signing on Behalf of an Entity)

 

[Signature Page to Lock-up Agreement]

 

 

 

 

  Very truly yours,
   
  Mark Tompkins
   
  Mark Tompkins
  (Print Name of Stockholder)
   
  /s/ Mark Tompkins
  (Signature)
   
  N/A
  (Name and Title of Signatory, if Signing on Behalf of an Entity)

 

[Signature Page to Lock-up Agreement]

 

 

 

  Very truly yours,
   
  RAF, L.P.
   
  By: RAF GP, LLC, its general partner
   
  (Print Name of Stockholder)
   
  /s/ Joshua Garcia
  (Signature)
   
  Joshua Garcia, Authorized Signatory
  (Name and Title of Signatory, if Signing on Behalf of an Entity)

 

[Signature Page to Lock-up Agreement]

 

 

 

 

  Very truly yours,
   
  REDCO I, L.P.
   
  By: Redco I, (GP), LLC its general partner
   
  (Print Name of Stockholder)
   
  /s/ Joshua Garcia
  (Signature)
   
  Joshua Garcia, Authorized Signatory
  (Name and Title of Signatory, if Signing on Behalf of an Entity)

 

[Signature Page to Lock-up Agreement]

 

 

 

 

  Very truly yours,
   
  REDMILE CAPITAL FUND, LP
   
  By: Redmile Group, LLC, its investment manager
   
  (Print Name of Stockholder)
   
  /s/ Joshua Garcia
  (Signature)
   
  Joshua Garcia, Authorized Signatory
  (Name and Title of Signatory, if Signing on Behalf of an Entity)

 

[Signature Page to Lock-up Agreement]

 

 

 

 

  Very truly yours,
   
  REDMILE CAPITAL OFFSHORE II MASTER FUND, LTD.
   
  By: Redmile Group, LLC, its investment manager
   
  (Print Name of Stockholder)
   
  /s/ Joshua Garcia
  (Signature)
   
  Joshua Garcia, CFO and Authorized Signatory
  (Name and Title of Signatory, if Signing on Behalf of an Entity)

 

[Signature Page to Lock-up Agreement]

 

 

 

 

  Very truly yours,
   
  REDMILE CAPITAL OFFSHORE MASTER FUND, LTD.
   
  By: Redmile Group, LLC, its investment manager
   
  (Print Name of Stockholder)
   
  /s/ Joshua Garcia
  (Signature)
   
  Joshua Garcia, CFO and Authorized Signatory
  (Name and Title of Signatory, if Signing on Behalf of an Entity)

 

[Signature Page to Lock-up Agreement] 

 

 

 

 

  Very truly yours,
   
  REDMILE STRATEGIC MASTER FUND, LP
   
  By: Redmile Group, LLC, its investment manager
   
  (Print Name of Stockholder)
   
  /s/ Joshua Garcia
  (Signature)
   
  Joshua Garcia, CFO and Authorized Signatory
  (Name and Title of Signatory, if Signing on Behalf of an Entity)

 

[Signature Page to Lock-up Agreement]

 

 

 

 

  Very truly yours,
   
  REDMILE PRIVATE INVESTMENTS II, L.P.
   
  By: Redmile Private Investments II (GP), LLC, its general partner
   
  By: Redmile Group, LLC, its managing member
   
  (Print Name of Stockholder)
   
  /s/ Joshua Garcia
  (Signature)
   
  Joshua Garcia, CFO and Authorized Signatory
  (Name and Title of Signatory, if Signing on Behalf of an Entity)

 

[Signature Page to Lock-up Agreement]

 

 

 

 

  Very truly yours,
   
  McKesson Ventures, LLC
   
  McKesson Ventures, LLC
  (Print Name of Stockholder)
   
  /s/ Jennifer Carter
  (Signature)
   
  Jennifer Carter   Partner & VP Operations
  (Name and Title of Signatory, if Signing on Behalf of an Entity)

 

[Signature Page to Lock-up Agreement]

 

 

 

 

  Very truly yours,
   
  A- Fund, L.P.
   
  By: A-Fund Investment Management, L.P.
  its General Partner
   
  By: A-Fund International, Ltd.
  its General Partner
   
  Matthew Bonner
  (Print Name of Stockholder)
   
  /s/ Matthew Bonner
  (Signature)
   
  Matthew Bonner   COO & Legal Partner
  (Name and Title of Signatory, if Signing on Behalf of an Entity)

 

[Signature Page to Lock-up Agreement]

 

 

 

  

  Very truly yours, 
   
  DCM VI, L.P.
   
  By: DCM Investment Management VI, L.P.
  Its General Partner
   
  By: DCM International VI, Ltd.
  Its General Partner
   
  Matthew Bonner
  (Print Name of Stockholder)
   
  /s/ Matthew Bonner
  (Signature)
   
  Matthew Bonner    COO & Legal Partner
  (Name and Title of Signatory, if Signing on Behalf of an Entity)

 

[Signature Page to Lock-up Agreement]

 

 

 

 

EXHIBIT A

 

Stockholder’s Shares

 

Stockholder:  Shares* 
Mark Tompkins   1,592,000 
A-Fund L.P.   16,006 
DCM VI. L.P.   3,200,727 
McKesson Ventures LLC   3,391,200 
RAF, L.P.   1,865,707 
Redmile Capital Fund LP   416,912 
Redmile Capital Offshore II Master Fund Ltd.   549,918 
Redmile Capital Offshore Master Fund Ltd.   129,512 
Redmile Private Investments II, L.P.   4,408,522 
Redmile Strategic Master Fund L.P.   26,332 
RedCo. I L.P.   4,000,000 

 

*As may be adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification effected after the date hereof.

 

 

 

 EX-101.SCH 3 augx-20210222.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 augx-20210222_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Entity Information, Former Legal or Registered Name EX-101.PRE 5 augx-20210222_pre.xml XBRL PRESENTATION FILE XML 6 ea136641-8k_augmedix_htm.xml IDEA: XBRL DOCUMENT 0001769804 2021-02-22 2021-02-22 iso4217:USD shares iso4217:USD shares 0001769804 false 8-K 2021-02-22 AUGMEDIX, INC. DE 000-56036 83-3299164 1161 Mission Street Suite B-100 San Francisco CA 94103 (888) 669-4885 N/A false false false false true false XML 7 R1.htm IDEA: XBRL DOCUMENT v3.20.4
Cover
Feb. 22, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Feb. 22, 2021
Entity File Number 000-56036
Entity Registrant Name AUGMEDIX, INC.
Entity Central Index Key 0001769804
Entity Tax Identification Number 83-3299164
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 1161 Mission Street
Entity Address, Address Line Two Suite B-100
Entity Address, City or Town San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94103
City Area Code (888)
Local Phone Number 669-4885
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Entity Information, Former Legal or Registered Name N/A
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.4 html 1 96 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://augmedix.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ea136641-8k_augmedix.htm augx-20210222.xsd augx-20210222_lab.xml augx-20210222_pre.xml ea136641ex10-1_augmedix.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ea136641-8k_augmedix.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "ea136641-8k_augmedix.htm" ] }, "labelLink": { "local": [ "augx-20210222_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "augx-20210222_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "augx-20210222.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 60, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "AUGX", "nsuri": "http://augmedix.com/20210222", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "ea136641-8k_augmedix.htm", "contextRef": "From2021-02-22to2021-02-22", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://augmedix.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "ea136641-8k_augmedix.htm", "contextRef": "From2021-02-22to2021-02-22", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationFormerLegalOrRegisteredName": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Former Legal or Registered Name of an entity", "label": "Entity Information, Former Legal or Registered Name" } } }, "localname": "EntityInformationFormerLegalOrRegisteredName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://augmedix.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 14 0001213900-21-012025-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-21-012025-xbrl.zip M4$L#!!0 ( MR6E(HF\E$.P, (8, 1 875G>"TR,#(Q,#(R,BYX M.L 6H,9(KR<'\?24O M8,!0EI8GZ>J
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end